{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:28:34Z","timestamp":1786620514304,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.gore.2025.101680","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T17:58:13Z","timestamp":1737482293000},"page":"101680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1517-8829","authenticated-orcid":false,"given":"Salamatu","family":"Abdul-Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaraj","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep S","family":"Sagoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asima","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gore.2025.101680_b0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl Cancer Inst."},{"issue":"Suppl 3","key":"10.1016\/j.gore.2025.101680_b0010","first-page":"A83","article-title":"PR077\/#722 Patient and public involvement in designing a willingness to pay survey for a PARP inhibitor de-escalation study IPIROC in ovarian cancer: a UK- India experience","volume":"34","author":"Abdul-Aziz","year":"2024","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"1","key":"10.1016\/j.gore.2025.101680_b0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2008.10.008","article-title":"Aggressive and complex surgery for advanced ovarian cancer: an economic analysis","volume":"112","author":"Aletti","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0020","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2023-004563","article-title":"Exploring international differences in ovarian cancer care: a survey report on global patterns of care, current practices, and barriers","volume":"33","author":"Algera","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11888-013-0181-6","volume":"9","author":"Andr\u00e9","year":"2013","journal-title":"Curr. Colorectal Cancer Rep."},{"issue":"28_suppl","key":"10.1016\/j.gore.2025.101680_b0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1200\/JCO.2022.40.28_suppl.254","article-title":"\u201cIt sounds very negative\u201d: patient perspectives on de-escalation of treatment concept and language","volume":"40","author":"Andrews","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.101680_b0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajog.2021.12.012","article-title":"Risk factors for financial toxicity in patients with gynecologic cancer","volume":"226","author":"Aviki","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.gore.2025.101680_b0040","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2025.101680_b0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/AOG.0000000000002317","article-title":"Cost of care for the initial management of ovarian cancer","volume":"130","author":"Bercow","year":"2017","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1634\/theoncologist.2013-0359","article-title":"Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects","volume":"19","author":"Beusterien","year":"2014","journal-title":"Oncologist."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/00019053-200017020-00003","article-title":"Pharmacoeconomic considerations in treating ovarian cancer","volume":"17","author":"Bodurka-Bevers","year":"2000","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"10.1016\/j.gore.2025.101680_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.04.003","article-title":"Financial toxicity in gynecologic oncology","volume":"154","author":"Bouberhan","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0065","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1136\/ijgc-2024-005363","article-title":"Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients","volume":"34","author":"Bruno","year":"2024","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"5","key":"10.1016\/j.gore.2025.101680_b0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1634\/theoncologist.6-5-441","article-title":"Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients","volume":"6","author":"Calhoun","year":"2001","journal-title":"Oncologist."},{"key":"10.1016\/j.gore.2025.101680_b0075","unstructured":"CancerCare. Patient Access & Engagement Report. New York; 2016."},{"issue":"8","key":"10.1016\/j.gore.2025.101680_b0080","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21443","article-title":"The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment","volume":"68","author":"Carrera","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.gore.2025.101680_b0090","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/ijgc-2023-004740","article-title":"Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"10106","key":"10.1016\/j.gore.2025.101680_b0095","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.31557\/APJCP.2021.22.3.671","article-title":"Out-of-Pocket, Catastrophic health expenditure and distress financing on non-communicable diseases in India: a systematic review with meta-analysis","volume":"22","author":"Dhankhar","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0105","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2025.101680_b0110","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1007\/s00520-022-07044-z","article-title":"Financial toxicity of cancer care in low-and middle-income countries: a systematic review and meta-analysis","volume":"30","author":"Donkor","year":"2022","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.gore.2025.101680_b0115","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"10191","key":"10.1016\/j.gore.2025.101680_b0120","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.gore.2025.101680_b0125","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1007\/s11136-022-03193-0","article-title":"Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective","volume":"31","author":"Fiteni","year":"2022","journal-title":"Qual. Life Res."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0130","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus A","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2020.08.003","article-title":"Cost-effectiveness analysis comparing \u201cPARP inhibitors-for-all\u201d to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer","volume":"159","author":"Gonzalez","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"25","key":"10.1016\/j.gore.2025.101680_b0140","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0145","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur. J. Cancer."},{"issue":"1","key":"10.1016\/j.gore.2025.101680_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hec.763","article-title":"Estimating the monetary value of health care: lessons from environmental economics","volume":"12","author":"Hanley","year":"2003","journal-title":"Health Econ."},{"issue":"1","key":"10.1016\/j.gore.2025.101680_b0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajog.2021.01.029","article-title":"Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer","volume":"225","author":"Harrison","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","volume":"120","author":"Jensen","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.101680_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz084","article-title":"Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis","volume":"3","author":"Karanth","year":"2019","journal-title":"JNCI Cancer Spectr."},{"issue":"12","key":"10.1016\/j.gore.2025.101680_b0175","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/sj.bjc.6601445","article-title":"Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice","volume":"89","author":"Koedoot","year":"2003","journal-title":"Br. J. Cancer."},{"issue":"8","key":"10.1016\/j.gore.2025.101680_b0180","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ijgc-2018-000125","article-title":"Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Kumar","year":"2019","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"15","key":"10.1016\/j.gore.2025.101680_b0185","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0190","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease\u2606","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2025.101680_b0195","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0200","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2020.12.015","article-title":"Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients","volume":"160","author":"Liang","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0205","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/healthcare10102099","article-title":"The burden of out-of-pocket expenditure related to gynaecological cancer in Malaysia","volume":"10","author":"Liew","year":"2022","journal-title":"Healthcare."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0210","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1007\/s00520-020-05620-9","article-title":"Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review","volume":"28","author":"Longo","year":"2020","journal-title":"Support Care Cancer."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0215","first-page":"117","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"JCNI"},{"issue":"5","key":"10.1016\/j.gore.2025.101680_b0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.7075","article-title":"Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs","volume":"4","author":"Miller","year":"2021","journal-title":"JAMA Netw. Open."},{"issue":"22","key":"10.1016\/j.gore.2025.101680_b0225","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 4","key":"10.1016\/j.gore.2025.101680_b0230","first-page":"A197","article-title":"EP290\/#820 Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): origin and feasibility of implementing a proof-of-concept exploratory study","volume":"33","author":"Mukhopadhyay","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"8","key":"10.1016\/j.gore.2025.101680_b0235","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/bjc.2014.91","article-title":"Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules","volume":"110","author":"Murray","year":"2014","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.gore.2025.101680_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.987337","article-title":"Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China","volume":"13","author":"Nie","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0245","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0272989X9601600314","article-title":"When do the \u201cDollars\u201d make sense?:Toward a conceptual framework for contingent valuation studies in health care","volume":"16","author":"O'Brien","year":"1996","journal-title":"Med. Decis. Making."},{"issue":"1","key":"10.1016\/j.gore.2025.101680_b0250","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11764-018-0723-7","article-title":"Financial toxicity is more than costs of care: the relationship between employment and financial toxicity in long-term cancer survivors","volume":"13","author":"Pearce","year":"2019","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.gore.2025.101680_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2023.05.060","article-title":"Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial","volume":"175","author":"Peipert","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2025.101680_b0260","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1007\/s00520-022-07053-y","article-title":"Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature","volume":"30","author":"Pergialiotis","year":"2022","journal-title":"Support Care Cancer"},{"issue":"34","key":"10.1016\/j.gore.2025.101680_b0265","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.20.01382","article-title":"Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors","volume":"38","author":"Piccart","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2025.101680_b0270","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.gore.2025.101680_b0275","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40273-015-0304-9","article-title":"Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review","volume":"33","author":"Poonawalla","year":"2015","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.gore.2025.101680_b0280","first-page":"A241","article-title":"EV309\/#479 Identifying opportunities and challenges to improve survival and quality of life for women with ovarian cancer in low- and middle-income countries: the every woman study","volume":"34","author":"Reid","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.gore.2025.101680_b0285","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/annonc\/mdt326","article-title":"The role of generic medicines and biosimilars in oncology in low-income countries","volume":"24","author":"Renner","year":"2013","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2025.101680_b0290","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1002\/cam4.3891","article-title":"Patient perspectives on chemotherapy de-escalation in breast cancer","volume":"10","author":"Rocque","year":"2021","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.gore.2025.101680_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001653","article-title":"Advancing oncology drug therapies for sub-Saharan Africa","volume":"3","author":"Sharma","year":"2023","journal-title":"PLOS Global Public Health."},{"issue":"22","key":"10.1016\/j.gore.2025.101680_b0300","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.3390\/cancers14225559","article-title":"Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling","volume":"14","author":"Smith","year":"2022","journal-title":"Cancers."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajog.2019.04.005","article-title":"Total and out-of-pocket costs of different primary management strategies in ovarian cancer","volume":"221","author":"Suidan","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"7","key":"10.1016\/j.gore.2025.101680_b0310","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/1471-0528.17041","article-title":"Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study","volume":"129","author":"Sundar","year":"2022","journal-title":"BJOG."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0315","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"26","key":"10.1016\/j.gore.2025.101680_b0320","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2025.101680_b0325","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2017.12.015","article-title":"Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase","volume":"148","author":"Tran","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.gore.2025.101680_b0330","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1002\/cncr.32961","article-title":"Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians","volume":"126","author":"Williams","year":"2020","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.gore.2025.101680_b0335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.33287","article-title":"Quantifying treatment preferences and their association with financial toxicity in women with breast cancer","volume":"127","author":"Williams","year":"2021","journal-title":"Cancer."},{"issue":"4","key":"10.1016\/j.gore.2025.101680_b0340","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2025.101680_b0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jss.2019.08.027","article-title":"Complications and survivorship trends after primary debulking surgery for ovarian cancer","volume":"246","author":"Xu","year":"2020","journal-title":"J. Surg. Res."},{"issue":"12","key":"10.1016\/j.gore.2025.101680_b0350","first-page":"1219","article-title":"Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Zhong","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:39:56Z","timestamp":1739842796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":70,"alternative-id":["S2352578925000050"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101680","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101680"}}